

Inventor(s): DUNICAN et al.

Appl. No.: 09

531,266

Series Code ↑

Serial No. ↑

Filed: March 20, 2000

Hon. Commissioner of Patents

Washington, D.C. 20231

Group Art Unit 1652

Examiner:

Steadman, D. J.

Atty. Dkt. P

258100

990288 BT

M#

Client Ref

Appln. Title:

New nucleotide sequences which code for the tal gene

Sir:

REPLY/AMENDMENT/LETTER

TECH CENTER 1600/2900 Date: May 14, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☒ NOT made
 B. ☐ Withdrawn
 C. ☐ made herewith
 D. ☐ made previously

For B & C
 See **Required**
Separate Paper
 (Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	80	**minus 80 0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	7	***minus 7 0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave blank if this is a reissue application)	add	+ \$280/\$140 =	+ \$0	104/204	
5. Original due Date: May 25, 2000	<input type="checkbox"/> NONE				
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) (2 mos) (3 mos) (Usable only for ≤ 2mo.OA --- 4 mos) (Usable only for 30 day/1mo.OA --- 5 mos)	\$110/\$55 = \$400/\$200 = \$920/\$460 = \$1,440/\$720= \$1,960/\$980=	+ \$0		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract		- \$0			
8.		Extension Fee	+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee		+ \$110/\$55	+ \$0		148/248
10. If IDS attached requires Official Fee under Rule 97 (c),	add	+ \$180	+ \$0		126
or if Rule 97(d) Request	add	+ \$180			126
11. After-Final Request Fee per rules 129(a) and 17(r)		+ \$740/370	+ \$0		146/246
12. No. of additional inventions for examination per Rule 129(b)		x \$740/370 ea	+ \$0		149/249
13. Request for Continued Examination (RCE)		+ \$740/370	+ \$0		1179/1279
14. Petition fee for			+ \$0		
15.		TOTAL FEE =	\$0		

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 21123

258100

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
 Intellectual Property Group

By Atty: Michael A. Sanzo

Reg. No. 36912

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Sig:

Andrew McManis 50,535
 for Mr. Sanzo

Fax: (703) 905-2500

Tel: (703) 905-2173

Atty/Sec: MAS/AMX

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

#15/E
no
05/20/02

RECEIVED

MAY 15 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Duncan, *et al.*

Appl. No.: 09/531,266

Filed: March 20, 2000

For: **New Nucleotide Sequences
Which Code for the TAL Gene**

Art Unit: 1652

Examiner: Steadman, D.

Atty. Dkt. 21123/258100

Response to Notice of Non-Compliant Amendment

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice of Non-Compliant Amendment dated April 25, 2002, and further to a May 2, 2002 teleconference with Examiner Steadman, Applicants enclose a duplicate copy of the Amendment filed on April 11, 2002 with an Appendix (numbered as pages 12-14) attached. The Appendix is captioned "Version with Markings to Show Changes Made."

Applicants' representatives appreciate Examiner Steadman's assistance in resolving this issue. If, in the opinion of the Examiner, a phone call may help to expedite the prosecution of this application, the Examiner is invited to telephone Applicants' representatives at (703) 905-2173.

Respectfully submitted,

PILLSBURY WINTHROP LLP


By: Andrew McAleavey
Andrew McAleavey
Reg. No. 50,535

Date: May 14, 2002
1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000

RECEIVED

MAY 15 2002

TECH CENTER 1600/23



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Dunican, *et al.*

Appl. No.: 09/531,266

Filed: March 20, 2000

For: **New Nucleotide Sequences
Which Code for the TAL Gene**

Art Unit: 1652

Examiner: Steadman, D.

Atty. Dkt. 21123/258100

Amendment and Response Under 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated December 14, 2001, Applicants respectfully request reconsideration of the above-captioned application in view of the following amendments and remarks.

Amendments

In the Abstract

Please delete the text of the abstract presently in the application from page 40. Please add the following text in its place:

ca' -- The invention is directed to DNA sequences from coryneform bacteria which encode a protein having transaldolase enzymatic activity. The invention also encompasses methods for the fermentative production of L-amino acids using bacteria in which the gene encoding transaldolase is amplified. --

In the Specification:

On page 1 of the application, after the title and immediately above the text on line 2, please add the heading -- Field of the Invention --.